UPLC-MS/MS法同时测定人血浆中氯吡格雷及其代谢物的浓度
x

请在关注微信后,向客服人员索取文件

篇名: UPLC-MS/MS法同时测定人血浆中氯吡格雷及其代谢物的浓度
TITLE:
摘要:

目的:建立同时测定人血浆中氯吡格雷(CLO)及其活性代谢产物(CATM)、非活性代谢产物(CCAM)浓度的方法,并用

于药动学研究。方法:取烷化剂2-溴-3′-甲氧基苯乙酮(MPB)保护的血浆样品,经乙腈沉淀蛋白后,以卡马西平为内标,采用超高

效液相色谱-串联质谱(UPLC-MS/MS)法测定。色谱柱为Waters ACQUITY UPLC HSS T3,流动相为水(含0.1%甲酸)-乙腈(含

0.1%甲酸),梯度洗脱,流速为0.50 ml/min。采用电喷雾电离源(ESI),多反应监测(MRM)方式进行正离子监测,用于定量分析的

离子对分别为m/z 322.1→211.8(CLO)、m/z 504.1→155.0(CATM烷化衍生物,CATMD)、m/z 308.3→198.0(CCAM)、m/z 273.2→

194.3(内标)。结果:CLO、CATMD、CCAM血药浓度分别在0.03~20.00、0.30~200.00、10.00~10 000.00 ng/ml 范围内线性关系良

好;日内、日间RSD<15%,相对误差(RE)为-3.5%~5.7。5 名健康受试者单剂量口服CLO 300 mg后,CLO、CATM、CCAM的

cmax分别为(7.89±5.46)、(15.58±8.08)、(8 023.33±1 047.39)ng/ml,tmax分别为(1.25±0.43)、(1.25±0.43)、(1.67±0.29)h,t1/2分别

为(2.31±0.61)、(0.64±0.08)、(6.53±2.55)h,AUC0-t分别为(17.19±14.59)、(21.39±9.58)、(30 648.85±8 026.63)ng·h/ml。结

论:该方法操作简便、灵敏度高、分析时间短,适用于CLO及其代谢物血药浓度测定及药动学研究。

ABSTRACT:

OBJECTIVE:To establish the method for the simultaneous determination of clopidogrel(CLO)and its active

metabolites(CATM)and inactive metabolites(CCAM),and to conduct pharmacokinetic study. METHODS:The plasma sample

had been derivatized by 2-bromine-3′ -methoxy acetophenone(MPB),and was precipitated by acetonitrile. Using carbamazepine

as internal standard,UPLC-MS/MS was adopted. The separation was performed on Waters ACQUITY UPLC HSS T3

column with mobile phase consisted of water(containing 0.1% formic acid)-acetonitrile(containing 0.1% formic acid)using a

gradient elution program at the flow rate of 0.50 ml/min. The ESI was equipped and quantitative analysis was operated in positive

ion and MRM mode. The mass transition ion-pairs were followed as m/z 322.1→211.8(CLO),m/z 504.1→155.0(the alkylation

derivatives of CATM,CATMD),m/z 308.3→198.0(CCAM),m/z 273.2→194.3(internal standard). RESULTS:The linear

calibration curves for CLO,CATMD and CCAM were obtained in the concentration range of 0.03-20.00 ng/ml,0.30-200.00

ng/ml and 10.00-10 000.00 ng/ml in plasma,respectively;intra-day and inter-day RSD for them were all less than 15%,and

relative error(RE)ranged from -3.5% to 5.7%. Main pharmacokinetic parameters of CLO,CATMD and CCAM in 5 healthy

volunteers after oral administration of CLO 300 mg were as follows:cmax were(7.89±5.46),(15.58±8.08),(8 023.33±

1 047.39)ng/ml;tmax were(1.25±0.43),(1.25±0.43),(1.67±0.29)h;t1/2 were(2.31±0.61),(0.64±0.08),(6.53±2.55)h;

AUC0-t were(17.19±14.59),(21.39±9.58),(30 648.85±8 026.63)ng·h/ml. CONCLUSIONS:The established method is sensitive,

rapid and convenient,which is suitable for pharmacokinetic study and plasma concentration determination of CLO and its

metabolites.

期刊: 2015年第26卷第35期
作者: 孙增先,王海东,倪善红,程聪,刘乃丰
AUTHORS: SUN Zeng-xian,WANG Hai-dong,NI Shan-hong,CHENG Cong,LIU Nai-feng
关键字: 氯吡格雷;活性代谢产物;非活性代谢产物;超高效液相色谱-串联质谱法;血药浓度;药动学
KEYWORDS: Clopidogrel;Active metabolite;Inactive metabolite;UPLC-MS/MS;Plasma concentration;Pharmacokinetcs
阅读数: 202 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!